• Usage of remdesivir has been associated with various adverse health effects, including liver damage and gastrointestinal issues, such as vomiting or nausea.

102/155 (66%) of remdesivir recipients in a clinical trial conducted among severe COVID-19 patients in Wuhan, China reported adverse health effects. “The most common adverse events in the remdesivir group were constipation, hypoalbuminaemia, hypokalaemia, anaemia, thrombocytopenia, and increased total bilirubin; and in the placebo group, the most common were hypoalbuminaemia, constipation, anaemia, hypokalaemia, increased aspartate aminotransferase, increased blood lipids, and increased total bilirubin.”